

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 September 2023 (07.09.2023)



(10) International Publication Number
WO 2023/165615 A1

(51) International Patent Classification:

A61K 47/64 (2017.01) *A61P 35/00* (2006.01)

A61K 39/395 (2006.01)

(21) International Application Number:

PCT/CN2023/079640

(22) International Filing Date:

03 March 2023 (03.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/079307

04 March 2022 (04.03.2022) CN

(71) Applicant: **I-MAB BIOPHARMA CO., LTD.** [CN/CN];

Rm802, 8F, 1Bld., West Tower, 88 Shangke Rd., Pudong
New Area, Shanghai 201210 (CN).

(72) Inventors: **ZHANG, Yanni**; Rm802, 8F, 1Bld., West Tow-

er, 88 Shangke Rd., Pudong New Area, Shanghai 201210
(CN). **XU, Ke**; Rm802, 8F, 1Bld., West Tower, 88 Shangke
Rd., Pudong New Area, Shanghai 201210 (CN). **WANG,
Zhengyi**; Rm802, 8F, 1Bld., West Tower, 88 Shangke Rd.,
Pudong New Area, Shanghai 201210 (CN).

(74) Agent: **NTD UNIVATION INTELLECTUAL PROP-**

ERTY AGENCY LTD.; 10th Floor, Tower C, Beijing
Global Trade Center, 36 North Third Ring Road East,
Dongcheng District, Beijing 100013 (CN).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))



WO 2023/165615 A1

(54) Title: COMBINATION THERAPIES COMPRISING A KRAS INHIBITOR FOR THE TREATMENT OF CANCER

(57) **Abstract:** Provided herein are methods of treating a KRAS mutant cancer (e.g., a KRAS G12C mutant cancer or a KRAS G12D mutant cancer) in a subject, comprising administering to the subject an effective amount of an agent that blocks the interaction between CD47 and SIRP α and an effective amount of a KRAS inhibitor (e.g., a KRAS G12C inhibitor wherein the cancer is a KRAS G12C mutant cancer, or a KRAS G12D inhibitor wherein the cancer is a KRAS G12D mutant cancer). Also provided are methods of stimulating phagocytosis of a population of cancer cells that express a KRAS mutant protein (e.g., a KRAS G12C mutant protein or a KRAS G12D mutant protein) by macrophages, comprising contacting the population with an effective amount of a therapeutic agent that blocks the interaction between CD47 and SIRP α and an effective amount of a KRAS inhibitor (e.g., a KRAS G12C inhibitor wherein the KRAS mutant protein is a KRAS G12C mutant protein, or a KRAS G12D inhibitor wherein the KRAS mutant protein is a KRAS G12D mutant protein).